Predictive role of Trimprob associated with multiparametric MRI in the diagnosis of prostate cancer.

Post di Daniele Passerini

Oggi il fisico Clarbruno Vedruccio e la moglie Dott.ssa Carla Ricci - il primo come inventore del Bioscanner TRIMprob, la seconda come attiva collaboratrice del progetto - hanno informato i loro contatti della pubblicazione di uno studio (realizzato presso il Camargo Hospital, Cancer Center di San Paolo del Brasile - grande struttura di riferimento per tutta l'America Latina) sull'utilizzo del TRIMprob per la diagnosi del tumore prostatico (PCa) a confronto con la risonanza magnetica multiparametrica (MRI). 

È risultato che il valore predittivo del Trimprob in pazienti sottoposti a biopsia (PB) è pari a quello della MRI e che l'integrazione tra i due sistemi insieme permette il miglior risultato nella diagnosi del tumore.

Riporto l'abstract presente su PubMed al link https://www.ncbi.nlm.nih.gov/pubmed/27649108 .

L'articolo può essere scaricato in formato pdf dal seguente link:

https://www.researchgate.net/publication/308875656_Predictive_role_of_Trimprob_associated_with_multiparametric_MRI_in_the_diagnosis_of_prostate_cancer

***

Int Braz J Urol. 2016 Sep 20. doi: 10.1590/S1677-5538.IBJU.2015.0714. [Epub ahead of print]

Predictive role of Trimprob associated with multiparametric MRI in the diagnosis of prostate cancer.

Guimaraes GC(1), Costa WH(1), Rosa RA(1), Zequi S(1), Favaretto R(1).
(1)Núcleo de Urologia, Departamento de Cirurgia Pélvica, AC Camargo Cancer Center, SP, Brasil.

Abstract

OBJECTIVES: To evaluate the predictive value of TRIMprob test to detect prostate cancer (PCa) in patients referred to prostate biopsy (PB).

MATERIAL AND METHODS: Patients with PSA <10ng/mL and rectal exam without findings suggestive of prostate cancer were selected for TRIMprob evaluation. Exam was performed by a single operator through transperineal approach. Patients admitted for the study were submitted to TRIMprob and multiparametric magnetic resonance (mpMRI) and posteriorly to PB.

RESULTS: In total, 77 patients were included. TRIMprob showed evidences of PCa in 25 (32.5%) and was negative in 52 patients (67.5%). The rate of detection of prostate cancer at biopsy was higher in patients with positive TRIMprob (16/25; 64.0%) than in patients with negative TRIMprob (11/52; 21.1%; p<0.001). Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of TRIMprob were respectively 61.5%, 82.0%, 64.0%, 80.3% and 74.0%. ROC curve showed the following areas under the curve values for TRIMprob, mpMRI and combination of TRIMprob + mpMRI: 0.706; 0.662 and 0.741 respectively. At combined analysis, when both TRIM¬prob and mpMRI were negative for prostate cancer, accuracy was 96.3% or only 1 in 27 PB was positive (3.7%).

CONCLUSIONS: Trimprob had similar predictive value for PCa in patients submitted to PB as mpMRI. Combined TRIMprob and mpMRI showed higher accuracy than when performed singly.

Copyright® by the International Brazilian Journal of Urology.

PMID: 27649108
[PubMed - as supplied by publisher]